Table 1.

Baseline Patient Characteristics by Treatment Group

Characteristic	Ceftaroline (n = 50)	Ceftriaxone (n = 50)	P Value
Age, mean (SD), y	63.4 (11.3)	65.4 (9.5)	.35
Male sex, no. (%)	50 (100)	48 (96)	.50
White race, no. (%)	41 (82)	37 (74)	.33
Weight, median (IQR), kg	98.6 (30.4)	93.7 (52.7)	.78
Platelet count, mean (SD), cells/μL	275.6 (117.4)	262.5 (131.5)	.61
Leukocyte count, mean (SD), cells/μL	10.4 (4.7)	10.9 (5.3)	.64
Duration of therapy, mean (SD), d	17.0 (15.8)	14.5 (16.9)	.44
Serum creatinine level at initiation, mean (SD), mg/dL	1.5 (1.2)	1.5 (1.3)	.91
No. of reported allergies at therapy initiation, no. (%)
0	19 (38)	12 (24)	.17
1	11 (22)	10 (20)
2	8 (16)	15 (30)
3	4 (8)	5 (10)
≥4	8 (16)	8 (16)
High-dose therapy,a no. (%)	1 (2)	8 (16)	.03
Treatment indication, no. (%)
ABSSSI	11 (22)	12 (24)
Bloodstream infection	5 (10)	2 (4)
Empyema	1 (2)	1 (2)
Infective endocarditis	1 (2)	2 (4)
Meningitis	0 (0)	1 (2)
Prosthetic joint infection	2 (4)	0 (0)
Pneumonia	6 (12)	17 (34)
Osteomyelitis	17 (34)	12 (24)
Septic arthritis	2 (4)	1 (2)
Combination of the above	5 (10)	2 (4)

Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; IQR, interquartile range; SD, standard deviation.

^aHigh-dose therapy was defined as 600 mg every 8 hours (or equivalent for renal function) for ceftaroline and ≥2 g/d for ceftriaxone